Investors showed interest in businesses tied to artificial intelligence infrastructure, advanced biotechnology, and quantum computing.
Why Is Boundless Bio, Inc. (BOLD) Stock Down Today?
Updated Nov 22, 2026 6:14 AM ET ยท Prev Close $2.38
Session Regime & Catalyst Assessment
68% Signal ConvictionBoundless Bio, Inc. Pulling Back 2.52% on 1.55x Relative Volume
Boundless Bio, Inc. (BOLD) is pulling back 2.52% (-$0.06) to $2.32 on 1.55x average session volume. Relative to benchmarks, BOLD is outperforming the S&P 500 by +1.12%. 14-day RSI stands at 35.0, keeping momentum in a bearish regime.
Investors showed interest in businesses tied to artificial intelligence infrastructure, advanced biotechnology, and quantum computing.
Price ($2.32) trades relative to 20-day SMA ($2.43) and 50-day SMA ($2.52).
Market & Sector Relative Strength
BOLD outperforming the S&P 500 by +1.12%Recent BOLD Catalyst Headlines
Verified WireBoundless Bio is set to merge with Serapha Bio, with the transaction set to close in the fourth quarter of 2026.
Combined company to operate as Serapha Bio and to advance Serapha s potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha s lead program Serp-01 targets the SERPINA1 E342K PiZZ m
Enrollment proceeding in Komodo-1 first-in-human clinical trial of Bbi-940 93 million in cash provides runway through expected clinical proof-of-concept readout for Komodo-1 San Diego, May 08, 2026 Globe Newswire -- Boun
1โ3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $2.43 (20-day SMA resistance) for directional breakout confirmation.
Technical Regime (BOLD)
BEARISH MA TRENDRetail & Crowd Sentiment
NeutralBullish sentiment dominates $BOLD on StockTwits with no new articles on Yahoo Finance.
About Boundless Bio, Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, Bbi-355, is a novel, oral, selective inhibitor of โฆ
Get Instant BOLD Catalyst Alerts
Receive an email alert when BOLD triggers an unusual volume breakout, options sweep, or rating shift.
BOLD Session & Catalyst FAQ
Why is BOLD stock down today?
Boundless Bio, Inc. (BOLD) is pulling back 2.52% (-$0.06) to $2.32 on 1.55x average session volume. Relative to benchmarks, BOLD is outperforming the S&P 500 by +1.12%. 14-day RSI stands at 35.0, keeping momentum in a bearish regime.
Is BOLD stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 1.55x relative volume (high participation). Our multi-factor model currently rates BOLD as AVOID NEW MONEY. Review full valuation, quality, and timing signals on the BOLD Buy or Sell Decision Brief โ
What is BOLD's intrinsic value and expected trading range?
At $2.32, BOLD's modeled 1-to-3 session range is $2.20 โ $2.44, with a key inflection level at $2.43 (20-day SMA resistance). Compare current price against multi-year cash flow projections in the BOLD Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for BOLD?
RSI at 35.0 reflects soft below-midline momentum. BOLD trades at $2.32 relative to its 20-day SMA ($2.43) and 50-day SMA ($2.52), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.